Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis

被引:361
作者
Haringman, JJ
Gerlag, DM
Zwinderman, AH
Smeets, TJM
Kraan, MC
Baeten, D
McInnes, IB
Bresnihan, B
Tak, PP
机构
[1] Univ Amsterdam, Acad Med Ctr, Div Clin Immunol & Rheumatol, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands
[3] State Univ Ghent Hosp, Dept Rheumatol, B-9000 Ghent, Belgium
[4] Univ Glasgow, Ctr Rheumat Dis, Glasgow G12 8QQ, Lanark, Scotland
[5] St Vincents Univ Hosp, Dept Rheumatol, Dublin, Ireland
关键词
D O I
10.1136/ard.2004.029751
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Previous work identified synovial sublining macrophage numbers as a potential biomarker for clinical efficacy in rheumatoid arthritis. Objective: To investigate the association between changes in infiltration of synovial macrophages and clinical improvement after antirheumatic treatment. Methods: 88 patients who participated in various clinical trials were studied. All patients underwent serial arthroscopy before initiation of treatment and after different time intervals. Immunohistochemical and digital image analysis were performed according to standardised procedures to detect changes in CD68+ synovial sublining macrophages in relationship to changes in the 28 joint count Disease Activity Score (DAS28). Statistical analysis was performed using one way analysis of variance, the independent samples t test, linear regression, and the standardised response mean (SRM). Results: For good, moderate, and non-responders, according to the DAS28 response criteria, there was a significant difference in the change in sublining macrophages ( mean (SEM) cells/mm(2) -643 ( 124), -270 ( 64), and -95 ( 60), respectively; p< 0.0003). There was a significant correlation between the change in the number of macrophages and the change in DAS28 ( Pearson correlation 0.874, p< 0.01). The change in sublining macrophages explained 76% of the variation in the change in DAS28 ( p< 0.02). The sensitivity to change of the biomarker was high in patients treated actively (SRM >0.8), whereas the ability to detect changes in placebo treated patients was weak (SRM <0.3). Conclusion: The results suggest that changes in synovial sublining macrophages can be used to predict possible efficacy of antirheumatic treatment.
引用
收藏
页码:834 / 838
页数:5
相关论文
共 33 条
[1]   THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].
ARNETT, FC ;
EDWORTHY, SM ;
BLOCH, DA ;
MCSHANE, DJ ;
FRIES, JF ;
COOPER, NS ;
HEALEY, LA ;
KAPLAN, SR ;
LIANG, MH ;
LUTHRA, HS ;
MEDSGER, TA ;
MITCHELL, DM ;
NEUSTADT, DH ;
PINALS, RS ;
SCHALLER, JG ;
SHARP, JT ;
WILDER, RL ;
HUNDER, GG .
ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324
[2]   Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis [J].
Boers, M ;
Verhoeven, AC ;
Markusse, HM ;
vandeLaar, MAFJ ;
Westhovens, R ;
vanDenderen, JC ;
vanZeben, D ;
Dijkmans, BAC ;
Peeters, AJ ;
Jacobs, P ;
vandenBrink, HR ;
Schouten, HJA ;
vanderHeijde, DMFM ;
Boonen, A ;
vanderLinden, S .
LANCET, 1997, 350 (9074) :309-318
[3]   Synovial biopsy in arthritis research: five years of concerted European collaboration [J].
Bresnihan, B ;
Tak, PP ;
Emery, P ;
Klareskog, L ;
Breedveld, F .
ANNALS OF THE RHEUMATIC DISEASES, 2000, 59 (07) :506-510
[4]   Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis - A randomized, double-blind, placebo-controlled, dose-escalation trial [J].
Choy, EHS ;
Isenberg, DA ;
Garrood, T ;
Farrow, S ;
Ioannou, Y ;
Bird, H ;
Cheung, N ;
Williams, B ;
Hazleman, B ;
Price, R ;
Yoshizaki, K ;
Nishimoto, N ;
Kishimoto, T ;
Panayi, GS .
ARTHRITIS AND RHEUMATISM, 2002, 46 (12) :3143-3150
[5]   The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis [J].
Cunnane, G ;
Madigan, A ;
Murphy, E ;
FitzGerald, O ;
Bresnihan, B .
RHEUMATOLOGY, 2001, 40 (01) :62-69
[6]   Targeting interleukin-1 in the treatment of rheumatoid arthritis [J].
Dayer, JM ;
Bresnihan, B .
ARTHRITIS AND RHEUMATISM, 2002, 46 (03) :574-578
[7]  
Dolhain RJEM, 1998, BRIT J RHEUMATOL, V37, P502
[8]   Expectation bias in rheumatoid arthritis clinical trials - The anti-CD4 monoclonal antibody experience - Commentary [J].
Epstein, WV .
ARTHRITIS AND RHEUMATISM, 1996, 39 (11) :1773-1780
[9]   Anti-TNFα therapy of rheumatoid arthritis:: what have we learned? [J].
Feldmann, M ;
Maini, RN .
ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 :163-196
[10]   Evolving concepts of rheumatoid arthritis [J].
Firestein, GS .
NATURE, 2003, 423 (6937) :356-361